Background: Type 2 sodium-glucose cotransporter inhibitors (SGLT2i) have shown clinical benefits in patients affected by chronic heart failure (CHF), but the mechanisms underlying their beneficial effects are still debated. Over the last years, SGLT2i showed its ability to improve left and right ventricular function, whereas its impact on atrial…